Magnesium and Sleep: What Clinical Trials Show About Recovery Quality

Magnesium is the fourth most abundant mineral in the human body. It participates in more than 300 enzymatic reactions: ATP synthesis, DNA replication, and regulation of neuromuscular transmission. Magnesium's connection to sleep stems from its role in two key inhibitory systems of the brain — GABAergic and NMDA-antagonistic. A systematic review by He et al., published in Nature and Science of Sleep (2025, DOI: 10.2147/NSS.S552646), summarized the mechanisms and clinical data on this topic.

How Does Magnesium Regulate Sleep at the Neurochemical Level?

Magnesium acts through three interconnected mechanisms that influence the brain's readiness to fall asleep and the quality of sleep:

• GABAergic enhancement. Magnesium potentiates transmission through GABA receptors — the main inhibitory neurotransmitter system. Its activation reduces neuronal excitability and facilitates the transition from wakefulness to sleep. When magnesium is lacking, inhibitory transmission weakens, manifesting as heightened excitability in the evening hours.
• NMDA antagonism. Magnesium blocks NMDA receptors, reducing the intracellular concentration of calcium in neurons and muscle cells. This promotes relaxation and reduces hyperexcitability — a state that makes it difficult to fall asleep when magnesium is deficient.
• Melatonin regulation. Magnesium is required for the activity of the enzyme serotonin-N-acetyltransferase, which participates in the synthesis of melatonin from serotonin. In animal models, magnesium deficiency led to reduced plasma melatonin. This mechanistically explains disrupted circadian rhythms under conditions of insufficient mineral intake.

What Do Randomized Controlled Trials Show?

The RCT evidence base is limited in sample size but consistent in the direction of effect. The review by He et al. (2025) presents the following trial data:

Abbasi et al. (2012)

A double-blind, placebo-controlled trial of 46 older adults with primary insomnia (Journal of Research in Medical Sciences, Iran). Intervention: 500 mg of magnesium oxide per day for 8 weeks. Results: significant reduction in the Insomnia Severity Index (ISI) by more than 8 points, along with increases in total sleep duration and sleep efficiency. Magnesium oxide has relatively low bioavailability (approximately 4–12%), meaning the actual dose of absorbed magnesium was substantially lower than stated.

Held et al. (2002)

RCT of 12 older adults (60–80 years), Pharmacopsychiatry. Magnesium supplementation over 4 weeks led to a significant increase in slow-wave sleep (deep sleep, stages three and four): from 10.1 to 16.5 minutes. Slow-wave sleep is the phase with the maximum release of growth hormone — most important for physical recovery and memory consolidation.

Nielsen et al. (2010)

100 participants, 320 mg magnesium citrate, 7 weeks. Significant improvement in the total score on the Pittsburgh Sleep Quality Index (PSQI). Magnesium citrate has better bioavailability than oxide.

Pilot RCT by Breus et al. (2024)

A crossover, placebo-controlled trial of 31 adult participants (mean age 46 years), Medical Research Archives. Intervention: 1 g of a proprietary magnesium blend per day for 2 weeks. The magnesium group showed significant improvements compared to placebo in several parameters: sleep duration, deep sleep, and sleep efficiency (p < 0.05). Limitations: small sample, proprietary supplement, short duration.

Who Is More Likely to Have Inadequate Magnesium Intake?

Dietary magnesium intake depends primarily on the proportion of whole foods in the diet: rich sources include pumpkin seeds, cashews and almonds, dark chocolate (more than 70% cocoa), legumes, spinach, and whole grains. Refined processing significantly reduces magnesium content in foods: for example, milling wheat removes more than 80% of its magnesium.

Groups at increased risk of inadequate intake or accelerated magnesium excretion:

• older adults — reduced intestinal absorption of magnesium and increased renal excretion;
• people with type 2 diabetes — glucosuria stimulates renal magnesium excretion;
• individuals with gastrointestinal disorders (Crohn's disease, celiac disease) — impaired intestinal absorption;
• people who regularly consume alcohol — it suppresses magnesium reabsorption in the kidneys;
• patients taking proton pump inhibitors long-term — these reduce magnesium absorption.

What Are the Limitations of the Evidence Base?

Despite biologically plausible mechanisms and positive RCT data, it is important to consider several limitations. Most trials were conducted on small samples (12–100 people) and over short periods (4–8 weeks). The forms of magnesium used differ in bioavailability — oxide, citrate, glycinate, and L-threonate behave differently. Direct comparative RCTs between forms with objective sleep measurement (polysomnography) are insufficient. Some trials were funded by supplement manufacturers, increasing the risk of reporting bias. The effect appears most well-supported in older adults with genuinely reduced magnesium status — this group shows the most consistent data.